Avestar Capital’s Novavax NVAX Stock Holding History

Avestar Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,069	Closed	-$203K	–	494
2024 Q2	$203K	Buy	+16,069	New	+$162K	0.02%	420

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Avestar Capital's NVAX Position: Q3 2024 in Review

Avestar Capital sold out of Novavax (NVAX) in Q3 2024, closing a stake of 16,069 shares — an estimated $203K sold.

Avestar Capital first reported a position in NVAX in Q2 2024 and held it in 1 quarter. The position peaked at $203K in Q2 2024. 237 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

Avestar Capital reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
Avestar Capital sold 16,069 Novavax shares in Q3 2024, an estimated $203K.
Avestar Capital first reported a position in Novavax in Q2 2024 and held it in 1 quarter.
Avestar Capital's Novavax position peaked at $203K in Q2 2024.
237 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on Avestar Capital's 13F filing for Q3 2024, filed 13 Nov 2024.